This document outlines information about glycopeptide antibiotics including vancomycin, teicoplanin, telavancin, and dalbavancin. It discusses their mechanisms of action, mechanisms of resistance, pharmacokinetics, clinical uses, and adverse reactions. Specifically, it notes that vancomycin inhibits bacterial cell wall synthesis, has activity against gram-positive bacteria, and is excreted by the kidneys. It is commonly used for infections caused by methicillin-resistant Staphylococcus aureus. Adverse reactions include phlebitis, "red man" syndrome, and in rare cases, ototoxicity or nephrotoxicity.